NCT02036645已完成1 期
A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 77
- 试验地点
- 11
- 主要终点
- Tolerability as Measured by Participant Withdrawal for an Adverse Event
研究概览
简要总结
The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Tolerability as Measured by Participant Withdrawal for an Adverse Event
时间窗: 4 months SAD; 7 months MAD
Tolerability measured by participant withdrawal for an adverse event from randomization through end of study
次要结局
- Mean Termination Half Life (t 1/2) of Medi1814(1 month)
- Maximum Plasma Concentration (Cmax) of Medi1814(1 month)
- Biomarkers: Amyloid-beta in Cerebral Spinal Fluid (Two Amyloid Bets Peptides of 40 and 42 Amino Acids Were Assessed)(Day 29 in SAD; Day 85 in MAD)
- Area Under the Concentration Time Curve (AUC) Time 0 to t (28 Days After 1st Dose SAD and MAD and After 3rd Dose in MAD, Day 57)(1 month)
- Biomarker: Total Amyloid-beta 1-42 in Plasma(Day 29 in SAD; Day 85 in MAD)
- Medi1814 Concentration in CSF Samples(SAD Day 29; MAD Day 85)
- Immunogenicity: Anti-drug Antibody Titer(4 months SAD (6 tests over 4 months; week 1, 2, 4, 8, 12, 16); 7 months MAD (7 monthly tests))
研究者
研究点 (11)
Loading locations...
相似试验
已完成
1 期
A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With PsoriasisPsoriasisNCT00925574Centocor, Inc.71
已完成
2 期
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi SyndromeOver-weightPrader-Willi SyndromeObesityNCT01818921Zafgen, Inc.17
已完成
1 期
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral InfarctionCerebral InfarctionNCT02378974CHABiotech CO., Ltd18
终止
2 期
Maintaining Suppression of Testosterone With Transdermal Estradiol GelCancer of the ProstateNCT02349386BHR Pharma, LLC34
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy ParticipantsHealthy ParticipantsNCT04763226Bristol-Myers Squibb46